Melanoma

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE)…

7 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…

7 months ago

Sona Announces Canadian Melanoma Clinical ‘Pilot’ Study Ethics Approval

Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an…

7 months ago

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation…

7 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Executive Chairman & CEO of the Company to Participate in a Fireside ChatPhiladelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) -…

7 months ago

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in…

7 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture…

7 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area…

7 months ago

OncoHost Named Gold Winner in 2025 Merit Awards for Business in Research & Development

BINYAMINA, Israel and CARY, N.C., July 9, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine…

7 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term…

7 months ago